Kodiak Sciences (NASDAQ:KOD) Given “Neutral” Rating at Chardan Capital

Chardan Capital reissued their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD) in a report published on Monday,Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other equities research analysts have also issued reports on KOD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Saturday, September 27th. Barclays upgraded Kodiak Sciences from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $7.00 to $17.00 in a report on Thursday, September 25th. Wall Street Zen raised shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 26th. Jefferies Financial Group assumed coverage on shares of Kodiak Sciences in a research report on Monday, September 22nd. They set a “buy” rating and a $15.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised shares of Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 target price on the stock in a research note on Thursday, August 14th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.20.

Kodiak Sciences Stock Performance

Shares of Kodiak Sciences stock opened at $14.65 on Monday. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $19.39. The company has a market capitalization of $773.81 million, a P/E ratio of -3.86 and a beta of 2.67. The company has a fifty day moving average of $10.37 and a 200 day moving average of $6.12.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.02). Analysts forecast that Kodiak Sciences will post -3.45 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its position in shares of Kodiak Sciences by 55.1% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company’s stock worth $7,668,000 after purchasing an additional 730,000 shares in the last quarter. Acadian Asset Management LLC grew its stake in Kodiak Sciences by 1.2% during the 2nd quarter. Acadian Asset Management LLC now owns 1,969,876 shares of the company’s stock worth $7,343,000 after buying an additional 23,742 shares during the last quarter. ICONIQ Capital LLC increased its position in Kodiak Sciences by 24.6% during the 1st quarter. ICONIQ Capital LLC now owns 1,266,563 shares of the company’s stock valued at $3,559,000 after buying an additional 249,699 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Kodiak Sciences by 90.1% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company’s stock valued at $1,922,000 after buying an additional 324,722 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its stake in Kodiak Sciences by 11.3% in the second quarter. Nantahala Capital Management LLC now owns 590,884 shares of the company’s stock valued at $2,204,000 after buying an additional 60,171 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.